Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23791762 | 0.93 | DUT (0.51) | DUTDGAT1LMNATSHRHTT | |
| SCHEMBL30851243 | 0.84 | DUT (0.41) | DUT | |
| SCHEMBL24968824 | 0.84 | DUT (0.41) | DUT | |
| SCHEMBL21608263 | 0.81 | DYRK1A (0.39) | RXFP1 | |
| SCHEMBL21608342 | 0.77 | RXFP1 (0.33) | RXFP1 | |
| SCHEMBL20348541 | 0.76 | HTR2C (0.46) | DUTLMNAHTT | |
| SCHEMBL21608321 | 0.76 | LMNA (0.37) | RXFP1LMNATSHRHTT | |
| SCHEMBL21608341 | 0.75 | RXFP1 (0.34) | RXFP1LMNATSHRHTT | |
| SCHEMBL2262948 | 0.75 | DUT (0.42) | DUT | |
| SCHEMBL20337987 | 0.75 | HTR2C (0.53) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210277003-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-09 | — | — | US | disclosed |
| WO-2019243535-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277003-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | DUT 1114/4885DGAT1 1163/4885RXFP1 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.